公司資料
Replimune Group 股價、新聞與催化劑
- 股票代碼:
- REPL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
14.63 USD (-2.27%)
收盤價
最後更新: 2026年8月17日
732M USD
市值
股價為何變動
The latest company update was “Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update”. REPL changed 1.45% and closed at $14.97 on Aug 14, 2026, indicating a relatively limited closing-price reaction to this earnings update.
公司概覽
Oncolytic Immunotherapy Platform
Replimune develops engineered herpes-simplex-virus-based immunotherapies that selectively replicate within tumors, directly destroy cancer cells, release tumor antigens, and stimulate systemic antitumor immunity. Its viruses are armed with immune-activating components intended to enhance local tumor killing and complement checkpoint inhibitors.
TUDRIQEV
TUDRIQEV, previously known as RP1, is an FDA-approved oncolytic therapy encoding a fusogenic GALV-GP-R protein and GM-CSF. It is approved under the accelerated approval pathway in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1 antibody-based regimen.
IGNYTE-3 Confirmatory Program
The global Phase 3 IGNYTE-3 study is evaluating TUDRIQEV plus nivolumab against physician's-choice therapy in advanced melanoma after anti-PD-1 treatment. The study is intended to verify clinical benefit and support continued approval, with overall survival as the primary endpoint.
RP2
RP2 builds on the same oncolytic HSV-1 backbone as TUDRIQEV and additionally expresses an anti-CTLA-4 antibody-like molecule. The design seeks to concentrate CTLA-4 blockade within tumors and tumor-draining lymph nodes while limiting systemic exposure.
Metastatic Uveal Melanoma
The registration-directed REVEAL study evaluates RP2 plus nivolumab against ipilimumab plus nivolumab in metastatic uveal melanoma. The Phase 2/3 trial uses overall survival and progression-free survival as primary endpoints.
未來催化劑
- US commercial launch of TUDRIQEV within 60 days of its August 6, 2026 FDA approval.
- Transition of the RP2 REVEAL study into Phase 3 in the first quarter of 2027.
- Primary overall-survival readout from the Phase 3 IGNYTE-3 confirmatory study in 2030.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。